

## ICMJE DISCLOSURE FORM

Date: August 4<sup>th</sup>, 2022

Your Name: Edyta Maria Urbanska

Manuscript Title: How should clinicians manage metastatic NSCLC patients with BRAF non-V600E mutations?

Manuscript number (if known): PCM-22-24

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	___ None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	

5	Payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events	Takeda, Amgen, Roche, Astra Zeneca, Novartis,	Payments were made to me for lectures and presentations.
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	MSD	Upcoming participation in IASLC WCLC 2022, Vienna, Austria, September 6-9
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Pfizer	Payments were made for advisory board.
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

**Please summarize the above conflict of interest in the following box:**

As mentioned in point 5, I have received honoraria from Takeda, Amgen, Roche, Astra Zeneca, and Novartis in the last 36 months for lectures and presentations, and from Pfizer for advisory board.  
As mentioned in point 7, I have received support from MSD for attending IASLC WCLC 2022, Vienna, Austria, September 6-9.  
I have no relationships/activities/interests to the current manuscript.

**Please place an "X" next to the following statement to indicate your agreement:**

**X** I certify that I have answered every question and have not altered the wording of any of the questions on this form.